Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application
      • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application
      • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
  1. IsoPet®
  2. Animal Studies
  3. Canine Studies

IsoPet® – Treating CANINE Sarcomas (SUCCESSFUL results)

IsoPet® | brand name of RadioGel™ used in veterinary applications

Dr. Maltz injecting ISOPET™ into the sedated Canine.
Dr. Maitz injecting ISOPET™ into the sedated pet.

Richland, WA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC PINK: RDGL) first therapy to canine treat soft tissue sarcoma is successful

Vivos Inc, a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, is pleased to report several significant outcomes after its signature product, IsoPet®, was used to treat a hind-leg soft-tissue sarcoma in a Sheltie at the University of Missouri Veterinary Health Center in Columbia, Missouri.


Veterinary oncologist, Dr. Charles Maitz, reported that the treatment of the sarcoma resulted in a “complete response,” meaning tumor destruction and disappearance, together with a healthy recovery. Results will be presented in at the Veterinary Cancer Society’s annual conference in Louisville, Kentucky, October 17 – 20, 2018.


After therapy the pet owner commented that the dog had more energy than she can remember for a long time. “The owner is delighted!” said Dr. Maitz.


Study investigators were also pleased that IsoPet® met all RadioGel™ design performance criteria. Post-treatment imaging and dosimetry provided confirmatory data addressing the principal questions previously raised by an FDA review panel, including:


  •  Near-uniform placement by injection and interstitial perfusion within the tumor without vascular clearance to normal organs and tissues
  •  Very high therapeutic ratios (radiation dose to the tumor relative to normal organs)
  •  Effective, highly localized, high-dose radiotherapy, and complete absence of adverse side-effects in critical normal tissues



The University of Missouri is now advertising availability of IsoPet® treatment for dogs and other species, including treatment of equine (horse) sarcoids.


Dr. Mike Korenko, Vivos Inc CEO stated “The successful treatment of the cat and dog subjects thus far increases the likelihood of IsoPet® becoming a practical solution in the treatment of animal cancer. Additionally, the data obtained at the University of Missouri will support the pre-clinical investigations required by the FDA to provide evidence that RadioGel™ can be safe and effective for treating various human cancers.”


Vivos, Inc.

Precision Radionuclide Therapy (PRnT)

OTCQB: RDGL

contact: info@radiogel.com


Home Page Cover Image: 

 

Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

 

Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® Therapy Application(s)


Precision Radionuclide Therapy (PRnT)


Vivos Inc.
 - (OTCQB: RDGL) Investor Relations 

Contact

 

Main colors
   bg-primary
   bg-primary-light
   bg-primary-dark
   bg-secondary
   bg-secondary-dark
Template sections
   body
   top-header
   header
   content
Footer Styles
   background
   text color
   link color
   horizontal line
Buttons
   style 1
   style 2
   style 3
Other elements
  social icons
  navigation color
  subnav background
Mobile navigation
   background color
   navigation color
Template configurations
has-right-nav g-font
navigation styles
size-15 weight-400 snip-nav
content styles
form-white
footer styles
o-form color-white
Typography
Heading H1
weight-600
Heading H2
weight-600
Heading H3
weight-600
Buttons
weight-600 is-uppercase
Animations

Note:
All changes made here will be applied to your entire website.
is-switcher admin-only

RadioGel™ Logo

Precision Radionuclide Therapy (PRnT)

draggable-logo

About | Privacy Policy | Cookie Policy | Sitemap
© 2023 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
Log out | Edit
  • Regional Clinics
  • IsoPet® Therapy Pets
  • Veterinarians
  • Animal Studies
    • Canine Studies
    • Feline Studies
  • Our IsoPet® Mission
  • Scroll to top